Livforsakringsbolaget Skandia’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $244K | Hold |
1,330
| – | – | 0.01% | 297 |
|
|
2025
Q4 | $234K | Hold |
1,330
| – | – | 0.01% | 317 |
|
|
2025
Q3 | $186K | Sell |
1,330
-100
| -7% | -$13.5K | 0.01% | 371 |
|
|
2025
Q2 | $179K | Hold |
1,430
| – | – | 0.01% | 406 |
|
|
2025
Q1 | $196K | Hold |
1,430
| – | – | 0.01% | 392 |
|
|
2024
Q4 | $219K | Hold |
1,430
| – | – | 0.01% | 379 |
|
|
2024
Q3 | $277K | Buy |
1,430
+1,200
| +522% | +$251K | 0.01% | 355 |
|
|
2024
Q2 | $53.3K | Sell |
230
-200
| -47% | -$43.5K | ﹤0.01% | 373 |
|
|
2024
Q1 | $92.7K | Hold |
430
| – | – | 0.01% | 320 |
|
|
2023
Q4 | $111K | Buy |
430
+263
| +157% | +$64.6K | 0.01% | 295 |
|
|
2023
Q3 | $42.9K | Hold |
167
| – | – | ﹤0.01% | 343 |
|
|
2023
Q2 | $47.6K | Hold |
167
| – | – | ﹤0.01% | 337 |
|
|
2023
Q1 | $46.4K | Hold |
167
| – | – | ﹤0.01% | 341 |
|
|
2022
Q4 | $46.2K | Hold |
167
| – | – | 0.01% | 341 |
|
|
2022
Q3 | $45K | Sell |
167
-900
| -84% | -$191K | 0.01% | 333 |
|
|
2022
Q2 | $218K | Sell |
1,067
-6,120
| -85% | -$1.25M | 0.02% | 323 |
|
|
2022
Q1 | $1.51M | Sell |
7,187
-13,900
| -66% | -$3.02M | 0.1% | 159 |
|
|
2021
Q4 | $5.06M | Sell |
21,087
-900
| -4% | -$231K | 0.32% | 78 |
|
|
2021
Q3 | $6.22M | Sell |
21,987
-200
| -0.9% | -$65.5K | 0.39% | 64 |
|
|
2021
Q2 | $7.68M | Buy |
22,187
+1,000
| +5% | +$303K | 0.46% | 50 |
|
|
2021
Q1 | $5.93M | Sell |
21,187
-300
| -1% | -$80.9K | 0.41% | 62 |
|
|
2020
Q4 | $5.26M | Buy |
21,487
+800
| +4% | +$206K | 0.45% | 47 |
|
|
2020
Q3 | $5.87M | Sell |
20,687
-400
| -2% | -$112K | 0.63% | 37 |
|
|
2020
Q2 | $5.64M | Buy |
21,087
+3,500
| +20% | +$1.05M | 0.64% | 34 |
|
|
2020
Q1 | $5.56M | Buy |
17,587
+500
| +3% | +$152K | 0.78% | 25 |
|
|
2019
Q4 | $5.07M | Sell |
17,087
-800
| -4% | -$222K | 0.6% | 37 |
|
|
2019
Q3 | $4.17M | Hold |
17,887
| – | – | 0.49% | 49 |
|
|
2019
Q2 | $4.18M | Buy |
17,887
+300
| +2% | +$69.3K | 0.51% | 47 |
|
|
2019
Q1 | $4.16M | Hold |
17,587
| – | – | 0.55% | 47 |
|
|
2018
Q4 | $5.29M | Hold |
17,587
| – | – | 0.79% | 27 |
|
|
2018
Q3 | $6.21M | Sell |
17,587
-5,100
| -22% | -$1.76M | 0.74% | 26 |
|
|
2018
Q2 | $6.58M | Buy |
22,687
+400
| +2% | +$112K | 0.6% | 35 |
|
|
2018
Q1 | $6.1M | Buy |
22,287
+1,900
| +9% | +$590K | 0.59% | 37 |
|
|
2017
Q4 | $6.5M | Sell |
20,387
-2,200
| -10% | -$706K | 0.62% | 36 |
|
|
2017
Q3 | $7.07M | Hold |
22,587
| – | – | 0.63% | 36 |
|
|
2017
Q2 | $6.13M | Hold |
22,587
| – | – | 0.56% | 42 |
|
|
2017
Q1 | $6.17M | Sell |
22,587
-8,100
| -26% | -$2.29M | 0.58% | 39 |
|
|
2016
Q4 | $8.7K | Sell |
30,687
-60,290
| -66% | -$17.9M | 0.44% | 42 |
|
|
2016
Q3 | $12.8M | Buy |
90,977
+53,290
| +141% | +$15.8M | 0.63% | 28 |
|
|
2016
Q2 | $9.11M | Hold |
37,687
| – | – | 0.4% | 52 |
|
|
2016
Q1 | $9.81M | Hold |
37,687
| – | – | 0.46% | 48 |
|
|
2015
Q4 | $11.5M | Buy |
37,687
+15,120
| +67% | +$4.34M | 0.54% | 44 |
|
|
2015
Q3 | $6.58M | Hold |
22,567
| – | – | 0.35% | 61 |
|
|
2015
Q2 | $9.12M | Hold |
22,567
| – | – | 0.45% | 46 |
|
|
2015
Q1 | $9.53M | Sell |
22,567
-1,100
| -5% | -$434K | 0.47% | 46 |
|
|
2014
Q4 | $8.03M | Sell |
23,667
-7,800
| -25% | -$2.52M | 0.38% | 55 |
|
|
2014
Q3 | $10.4M | Sell |
31,467
-4,000
| -11% | -$1.32M | 0.39% | 50 |
|
|
2014
Q2 | $11.2M | Buy |
35,467
+1,300
| +4% | +$391K | 0.4% | 49 |
|
|
2014
Q1 | $10.5M | Buy |
+34,167
| New | +$10.8M | 0.39% | 50 |
|
Other funds holding BIIB
VCM
VPM
Livforsakringsbolaget Skandia's BIIB Position: Q1 2026 in Review
Livforsakringsbolaget Skandia held its Biogen (BIIB) position steady in Q1 2026 at 1,330 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #297.
Livforsakringsbolaget Skandia first reported a position in BIIB in Q1 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q3 2016. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Livforsakringsbolaget Skandia held 1,330 shares of Biogen worth $244K as of Q1 2026.
- Livforsakringsbolaget Skandia left its Biogen share count unchanged in Q1 2026.
- Biogen made up 0.01% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #297 holding.
- Livforsakringsbolaget Skandia first reported a position in Biogen in Q1 2014 and has held it in 49 quarters since.
- Livforsakringsbolaget Skandia's Biogen position peaked at $12.8M in Q3 2016.
- 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.